Abstract

Neuroprotection of lithium for axotomized retinal ganglion cells (RGCs) is attributed to upregulated intraretinal Bcl-2. As lithium also upregulates brain-derived neurotrophic factor (BDNF) which can rescue axotomized RGCs, it is hypothesized that lithium could protect RGCs through BDNF. This study investigated this hypothesis and a possible relationship between the dose and protection of lithium. All adult experimental rats received daily intraperitoneal injections of lithium chloride (LiCl) at 30, 60 or 85 mg/kg·bw until they were euthanized 2, 7 or 14 days after left intraorbital optic nerve (ON) transection. Our results revealed that RGC densities promoted and declined with increased dose of LiCl and the highest RGC densities were always in the 60 mg/kg·bw LiCl group at both 7 and 14 day points. Similar promotion and decline in the mRNA and protein levels of intraretinal BDNF were also found at the 14 day point, while such BDNF levels increased in the 30 mg/kg·bw LiCl group but peaked in the 60 and 85 mg/kg·bw LiCl groups at the 7 day point. These findings suggested that lithium can delay the death of axotomized RGCs in a dose-dependent manner within a certain period after ON injury and such beneficial effect is interrelated with an upregulated level of intraretinal BDNF.

Highlights

  • Lithium has been used as a mood-stabilizer to treat human bipolar disorders for over half a century.In recent years, accumulating evidence demonstrated that lithium is a robust neuroprotective agent for certain central neurons [1,2,3,4,5,6,7,8]

  • Our previous study showed that olfactory ensheathing cells (OECs) transplanted into the ocular stump of transected optic nerve (ON) promoted the number of surviving retinal ganglion cells (RGCs) in the adult rats and up-regulated intraretinal expression of Brain-derived neurotrophic factor (BDNF) was associated with the enhanced RGC survival after OEC

  • Immunohistochemical staining with anti-BDNF antibody showed that BDNF protein expressed in the RGC layer (GCL) and inner plexiform layer (IPL) of the retina in both lithium chloride (LiCl) (60 mg/kg·bw) and Control groups

Read more

Summary

Introduction

Lithium has been used as a mood-stabilizer to treat human bipolar disorders for over half a century. Lithium promotes the survival of either retinal ganglion cells (RGCs) in vitro and axotomized RGCs in vivo after optic nerve (ON) crush in adult mice and rats [9,10,11]. Such protective effects of lithium have been attributed to upregulated expression of Bcl-2 in RGCs [9,10,11]. This study investigated the above hypothesis that lithium could protect axotomized RGCs after rat ON transection through upregulated intraretinal BDNF and explored the possible relationship between the dose and neuroprotective effect of lithium

Morphology of Surviving RGCs and Glial Cells
Mean Densities of Surviving RGCs
Western Blot Assay
Immunohistochemical Staining of BDNF in the Retina
Discussion
ON Transection
Treatments and Counting of FG-Labeled RGCs
RT-PCR Assay
Western Blot Analysis
Immunohistochemical Procedures
Statistical Analyses
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call